6709.TWO Advagene Biopharma Co. Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
20.80 TWD
Close of Nov 6, 2026
19.50 36.15
Market cap
TWD 1.44B
P/E
-
P/B
4.33x
ROE
-44.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6709.TWO undervalued?

Graham number

The Graham number of Advagene Biopharma Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Advagene Biopharma Co. Ltd. fundamental analysis

No fundamental analysis for Advagene Biopharma Co. Ltd. yet.

Advagene Biopharma Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Advagene Biopharma Co. Ltd.

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.

Full company profile